Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada

NCT01290393 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01290393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01290393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Terminated
Start date
September 26, 2011
Completion date
December 20, 2012
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus